| 吴文忠.小儿肺热咳喘口服液联合重组人干扰素?琢1b雾化吸入对呼吸道合胞病毒肺炎患儿T细胞亚群和炎性因子的影响[J].,2022,(8):1470-1474 |
| 小儿肺热咳喘口服液联合重组人干扰素?琢1b雾化吸入对呼吸道合胞病毒肺炎患儿T细胞亚群和炎性因子的影响 |
| Effect of Xiaoer-Feire-Kechuan Oral Solution Combined with Recombinant Human Interferon α1b Injections with Spray Inhalation on T Cell Subsets and Inflammatory Cytokines of Children with Respiratory Syncytial Virus Pneumonia |
| 投稿时间：2021-11-27 修订日期：2021-12-22 |
| DOI：10.13241/j.cnki.pmb.2022.08.014 |
| 中文关键词: 呼吸道合胞病毒肺炎 小儿肺热咳喘口服液 重组人干扰素α1b T细胞亚群 炎性因子 |
| 英文关键词: Respiratory syncytial virus pneumonia Xiaoer-feire-kechuan oral solution Recombinant human interferon α1b injections T cell subsets Inflammatory cytokines |
| 基金项目: |
|
| 摘要点击次数: 588 |
| 全文下载次数: 288 |
| 中文摘要: |
| 摘要 目的：探讨小儿肺热咳喘口服液联合重组人干扰素α1b雾化吸入对呼吸道合胞病毒肺炎（RSVP）患儿T细胞亚群和炎性因子的影响。方法：选择2020年7月到2021年7月我院收治的105例RSVP患儿，依照随机数字表法分为对照组（52例）和观察组（53例）。两组均给予常规治疗，在此基础上对照组给予重组人干扰素α1b雾化吸入治疗，观察组给予小儿肺热咳喘口服液联合重组人干扰素α1b雾化吸入治疗，两组均连续给予治疗7 d。治疗后进行临床疗效评价。比较两组的一般指标。比较两组治疗前后的外周血CD3+、CD4+、CD8+水平及血清肿瘤坏死因子-α（TNF-α）、C反应蛋白（CRP）、白介素-6（IL-6）水平。比较两组治疗过程中不良反应发生率。结果：观察组的临床总有效率较对照组高（P<0.05）。观察组的啰音消失时间、住院时间、体温复常时间及咳嗽减轻时间均明显比对照组短（P<0.05）。与治疗前比较，治疗后两组外周血CD3+、CD4+水平升高，外周血CD8+水平降低（P<0.05），观察组治疗后外周血CD3+、CD4+水平均明显比对照组高（P<0.05），外周血CD8+水平比对照组低（P<0.05）。两组治疗后血清TNF-α、IL-6、CRP水平均比治疗前低（P<0.05），同时治疗后观察组血清TNF-α、CRP、IL-6水平均明显比对照组低（P<0.05）。治疗期间两组不良反应发生率比较无差异（x2=0.501，P=0.479）。结论：小儿肺热咳喘口服液联合重组人干扰素α1b雾化吸入治疗RSVP患儿的临床疗效较好，有助于临床症状的控制，提高机体免疫功能，抑制炎症反应，且安全性较好。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effect of Xiaoer-feire-kechuan oral solution combined with recombinant human interferon α1b injections with spray inhalation on T cell subsets and inflammatory cytokines of children with respiratory syncytial virus pneumonia (RSVP). Methods: 105 cases of children with RSVP in our Hospital from July 2020 to July 2021 were selected. According to the random indicator method, they were divided into the control group(52 cases) and the observation group (53 cases). Children of the two groups were treated with conventional medicine, the control group were treated with recombinant human interferon α1b injections on this basis, the observation group were treated with Xiaoer-feire-kechuan oral solution combined with recombinant human interferon α1b injections with spray inhalation. The two groups were treated for 7 days. Clinical curative effect was evaluated after treatment. The general indexes of the two groups were compared. The peripheral blood levels of CD3+, CD4+, CD8+ and serum levels of Tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), interleukin-6(IL-6) of the two groups before and after treatment were compared. The adverse reaction incidence of two groups of patients during treatment were observed. Results: The total clinical effective rate of the observation group was higher than that of the control group(P<0.05). The rhonchus disappearance time,hospital stay time, body temperature relapse time and cough reduction time of the observation group were significantly less than that of the control group(P<0.05). Compared with before treatment, the levels of CD3+ and CD4+ in peripheral blood increased, and the level of CD8+ in peripheral blood decreased in the two groups after treatment(P<0.05). After treatment, the levels of CD3+ and CD4+ in peripheral blood of the observation group were higher than those of the control group(P<0.05). The level of CD8+ in peripheral blood was lower than that in control group (P<0.05). The levels of serum TNF-α, CRP, IL-6 of the two groups after treatment were significantly lower than before treatment(P<0.05), and levels of serum TNF-α, IL-6, CRP of the observation group were lower than that of the control group(P<0.05). At the same time, the levels of TNF-α, CRP and IL-6 of the observation group were significantly lower than those of the control group(P<0.05). There was no difference in the incidence of adverse reactions between the two groups during treatment(x2=0.501, P=0.479). Conclusion: Xiaoer-feire-kechuan oral solution combined with recombinant human interferon α1b injections with spray inhalation has good clinical efficacy in the treatment of children with RSVP, which is helpful to control clinical symptoms, improve immune function, inhibit inflammatory response, and has good safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
